A practical reference on post-marketing surveillance: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-09-19 and is reviewed periodically as new material appears.
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
Reported observations after unregulated use include shifts in skin pigmentation and, in some accounts, unintended changes to moles and other lesions. Whether these outcomes are causally linked to the compound, and how often they occur, remain open questions because controlled data are scarce. The absence of standardised dosing and verified product purity complicates interpretation. Researchers have called for better surveillance and analytical characterisation of samples obtained outside regulated channels. Conclusions drawn from anecdotal evidence should be treated as provisional.
Melanotan-2 has not received marketing authorisation from major regulatory agencies for any therapeutic indication. Several jurisdictions classify it as a prescription-only medicine or a controlled substance when supplied for human use. Because approved products do not exist, material sold online usually sits outside pharmaceutical supply chains and formal quality oversight. Regulators have issued public notices describing the compound as unapproved. Enforcement varies, and the legal position differs between countries, which complicates any single general statement about its status.
Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.
Melanocytes are the pigment-producing cells of the skin, and they carry melanocortin-1 receptors on their surface. When the receptor is activated, cyclic adenosine monophosphate rises inside the cell and raises the activity of enzymes such as tyrosinase, which increases melanin output. Melanotan-2 binds melanocortin-1 receptors in vitro and in animal models, and this binding is generally described as the basis for the tanning effect. Other receptors account for different effects: melanocortin-4 receptors contribute to appetite and erectile signalling, while melanocortin-3 and melanocortin-5 receptors contribute to energy balance and exocrine function.
Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Unapproved for therapeutic use | No marketing authorisation from major agencies |
| Legal classification | Varies by jurisdiction | Prescription-only or controlled in several countries |
| Common synonyms | Melanotan II; MT-II | Also referenced by catalogue codes |
| Typical analytical method | Reverse-phase HPLC | Often paired with mass spectrometry |
| Primary literature focus | Receptor pharmacology | Pigmentation and melanocortin signalling |
Identity and purity are assessed with chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the target peptide from related impurities and degradation products, and the resulting retention time is compared against a reference standard. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass. Amino acid analysis or peptide mapping can provide additional sequence-level confirmation when required. Results are only as reliable as the reference materials used alongside them.
Regulatory treatment varies by country. In the United States, melanotan-2 is not approved for any indication, and products marketed for human use fall outside the approved drug framework. Some other jurisdictions have placed it under prescription controls or listed it as a prohibited or restricted substance. Online listings frequently describe the material as a research chemical, a category that does not carry the same manufacturing and labelling requirements as approved medicines.
Solid peptide material is generally stable when kept cold and dry. Common practice is storage at -20 degrees Celsius or lower, with desiccant and protection from light. Repeated freeze-thaw cycles and exposure to moisture are associated with degradation, aggregation, or loss of material. Once dissolved, stability depends on solvent, concentration, and temperature, and solutions are usually treated as short-lived unless stability data support longer periods. Handling notes typically emphasise minimising time at ambient temperature.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
Lyophilised peptide powder is comparatively stable when kept dry, cold and protected from light. Once dissolved, the molecule is exposed to hydrolysis, oxidation and microbial growth, and degradation accelerates at higher temperatures and in alkaline solution. Repeated freeze-thaw cycles concentrate solutes and promote aggregation. Handling guidance for research peptides commonly clusters around freezer temperatures for powder and short refrigerated use for reconstituted solutions, with pH control and sterile technique applied throughout.
Verification of a purchased sample requires documentation linking a batch to a certificate of analysis, and that document should be read for the methods used rather than the headline purity figure. A single chromatographic percentage does not establish identity. Independent laboratories can perform identity and content assays, but no such test establishes that a product is suitable for human use. Claims about efficacy rest largely on small, early studies rather than on replicated controlled trials, and that gap remains open.
Identity testing for a cyclic peptide of this size usually relies on reversed-phase high-performance liquid chromatography coupled to mass spectrometry. The mass spectrum confirms molecular weight, while the chromatographic trace indicates the proportion of related impurities. Tandem mass spectrometry can provide sequence-level information when fragmentation data are compared against a reference standard. Nuclear magnetic resonance is sometimes used to confirm the lactam bridge, although it requires more material and greater operator expertise than routine chromatographic methods.
Some of the problems in Dalton's method were corrected by Joseph-Louis Gay-Lussac and Amedeo Avogadro. They developed ratio laws for gases similar to the laws developed for chemicals by Proust and Dalton. In 1811, Avogadro proposed that equal volumes of any two gases, at equal temperature and pressure, contain equal numbers of molecules (in other words, the mass of a gas's particles does not affect the volume that it occupies). Avogadro's hypothesis, now usually called Avogadro's law, provided a method for deducing the relative weights of the molecules of gaseous elements, for if the hypothesis is correct relative gas densities directly indicate the relative weights of the particles that compose the gases. This way of thinking led directly to a second hypothesis: the particles of certain elemental gases were pairs of atoms, and when reacting chemically these molecules often split in two. For instance, the fact that two liters of hydrogen will react with just one liter of oxygen to produce two liters of water vapor (at constant pressure and temperature) suggested that a single oxygen molecule splits in two in order to form two molecules of water. This give the correct formula of water, H2O, not HO. Avogadro measured oxygen's atomic weight to be 15.074.
=== Labour Party === In 1965, Hitchens joined the Labour Party on the very first day he was eligible to vote, but along with the majority of the Labour students' organization was expelled in 1967, because of what Hitchens called "Prime Minister Harold Wilson's contemptible support for the war in Vietnam". Since then he stated he had "re-enlisted a few times" back into the Labour Party. In a 2001 interview with Reason, he said that, in 1979, despite being a member of the Labour Party, he wasn't going to vote for them, nor could he bring himself to "vote Conservative." He abstained from voting. Hitchens stated that by not voting for the Labour Party he was effectively voting for Margaret Thatcher to win, which he said he had "secretly hoped would happen." In a 2005 Vanity Fair article, he endorsed Tony Blair in the 2005 general election, mainly due to his support for the 2003 invasion of Iraq. In a 2009 Slate article, he described that in the late 1970s the Labour Party moved to the right and stated that the downfall of the Labour Party came about upon Gordon Brown's becoming Prime Minister.
A = 1HPN (all IdoA(2S) residues in 2S0 conformation) Jmol viewer B = van der Waals radius space-filling model of A C = 1HPN (all IdoA(2S) residues in 1C4 conformation) Jmol viewer D = van der Waals radius space-filling model of C In these models, heparin adopts a helical conformation, the rotation of which places clusters of sulfate groups at regular intervals of about 17 angstroms (1.7 nm) on either side of the helical axis.
Sources: en.wikipedia.org
=== Binding mechanism === The receptor for advanced glycation end products (RAGE) is a multiligand member of the immunoglobulin superfamily, originally identified due to its ability to bind advanced glycation end products (AGEs). AGEs accumulate in various chronic conditions such as diabetes and renal failure. However, RAGE also binds other ligands, notably proteins of the S100/calgranulin family, such as EN-RAGE and S100B, which play significant roles in inflammatory processes. RAGE ligands interact with the receptor through its extracellular domain, triggering a cascade of intracellular signaling pathways. These pathways lead to the activation of key transcription factors like nuclear factor kappa B (NF-κB), which is central to the expression of proinflammatory cytokines, adhesion molecules (such as VCAM-1 and ICAM-1), and other mediators of inflammation. Upon binding ligands like EN-RAGE or S100B, RAGE stimulates various inflammatory responses, including endothelial cell activation, mononuclear cell migration, and the production of cytokines such as TNF-α and IL-1β. These interactions between RAGE and its ligands contribute to chronic inflammatory conditions, including atherosclerosis, Alzheimer's disease, and diabetic complications. Inhibiting the RAGE-ligand interaction—through the use of soluble RAGE (sRAGE) or specific antibodies—can suppress these inflammatory responses, offering potential therapeutic strategies.
As the raids were being conducted in Brussels, the Italian State Police executed two European Arrest Warrants in Italy. Maria Colleoni, Panzeri's wife, was arrested at their family home in Calusco d'Adda, near Bergamo, Italy, and his daughter, Silvia Panzeri, was arrested later that evening in Milan. Both women were transferred to a prison in Bergamo for detention. As of 14 December 2022, they had been released under house arrest to a property in Lombardy. Shortly thereafter, Italian authorities raided the Italian home of Francesco Giorgi, where an additional €20,000 in cash was confiscated. The European Arrest Warrant confirmed reports that the charges against Panzeri were related to corruption and gifts he had received from nation-states. The publication of the warrant was the first time that Morocco was implicated in the scandal. The day after the raids, on 10 December, a further search was conducted at the home of Belgian MEP Marc Tarabella, Vice Chair of the European Parliament's Delegation for relations with the Arab Peninsula. Tarabella had not yet been arrested. On 12 December 2022, it was announced that the Greek Anti-Money Laundering Authority had frozen all of Kaili's assets, as well as those of her close family members. This included her bank accounts, safes, companies, and any other financial assets. The head of the Anti-Money Laundering Authority noted that a newly established estate agency in Kolonaki, an upmarket neighbourhood of Athens, was of particular interest to the investigation.
==== Conditionality as the middle way – not-self and emptiness ==== The early Buddhist texts also associate dependent arising with emptiness and not-self. The early Buddhist texts outline different ways in which dependent origination is a middle way between different sets of "extreme" views (such as "monist" and "pluralist" ontologies or materialist and dualist views of mind-body relation). In the Kaccānagottasutta (SN 12.15, parallel at SA 301), the Buddha states that "this world mostly relies on the dual notions of existence and non-existence" and then explains the right view as follows:
=== Bibliography === "Annex A – Estate Baseline – 2009" (PDF). Defence Estates Development Plan (DEDP) 2009. GOV.UK (Report). Ministry of Defence. 3 July 2009. Retrieved 30 March 2023. Halley, James J (1988). RAF Squadrons. The Squadrons of the Royal Air Force & Commonwealth 1918–1988. Tonbridge, UK: Air Britain (Historians). ISBN 0-85130-164-9. Jackson, Paul (1986). Britain's Armed Forces Today: 4 RAF Germany. Shepperton, UK: Ian Allan. ISBN 0-7110-1579-1. Jefford, C. G. (1988). RAF Squadrons. A comprehensive record of the movement and equipment of all RAF squadrons and their antecedents since 1912. Shrewsbury, UK: Airlife. ISBN 1-85310-053-6. Langford, F. (1991). The Dorset Year Book - 1991. Dorset, UK: The Society Of Dorset Men. March, Peter R. (1992). Royal Air Force Yearbook 1992. Fairford, UK: Royal Air Force Benevolent Fund. March, Peter R. (1998). Royal Air Force Yearbook 1998. Fairford, UK: Royal Air Force Benevolent Fund. Sturtivant, Ray; Hamlin, John (2007). Royal Air Force flying training and support units since 1912. Tonbridge, UK: Air-Britain (Historians). ISBN 978-0851-3036-59.
Sources: en.wikipedia.org
Major regulatory agencies have not approved it for any indication. Some countries permit it only under prescription frameworks, while others classify it as a controlled substance.
Much of the evidence comes from case reports and accounts of unregulated use rather than controlled trials. Differences in product purity and dosing add further variability.
Laboratory work focuses on receptor binding and cellular signalling. Observational reports document outcomes after use, and analytical chemists examine samples to assess content and purity.
No. It is a laboratory-made peptide, while the natural hormone is alpha-melanocyte-stimulating hormone, a longer peptide produced by the pituitary gland and by skin cells. Melanotan-2 mimics only a short active region of that hormone and contains non-natural residues such as D-phenylalanine.